HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target
10/5/2026
Impact: 80
Healthcare
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on SpyGlass Pharma (NASDAQ: SGP) and maintained a price target of $37 for the stock.
AI summary, not financial advice
Share: